Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

776.38
8,081,685

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $775.43 -0.95 (-0.12%) 5:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum

Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum have been included in this Analyst Blog.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

Eli Lilly (LLY) closed at $331.60 in the latest trading session, marking a +1.44% move from the prior day.

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Thermo Fisher & TotalEnergies

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO), and TotalEnergies SE (TTE).

Strength Seen in H Lundbeck AS (HLUYY): Can Its 11.2% Jump Turn into More Strength?

H Lundbeck AS (HLUYY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed at $331.07 in the latest trading session, marking a +0.18% move from the prior day.

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.

Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study

Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.

Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's

The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $327.18, moving +0.76% from the previous trading session.

LabCorp (LH) to Strengthen Laboratory Footprint in Japan

LabCorp's (LH) Drug Development arm, in collaboration with BML, will open a 4,000-square meters lab facility in Kawagoe for global clinical trials.

The Zacks Analyst Blog Highlights Meta Platforms, Eli Lilly, The Home Depot, The Boeing Company, Vale

Meta Platforms, Eli Lilly, The Home Depot, The Boeing Company, Vale are part of Zacks top Analyst Blog.

Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?

Smart Beta ETF report for FVD

Sheraz Mian headshot

Top Analyst Reports for Meta Platforms, Eli Lilly & Home Depot

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Eli Lilly and Company (LLY), and The Home Depot, Inc. (HD).

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $327.27, marking a +0.51% move from the previous day.

Radius (RDUS) to Go Private With $890M Deal, Shares Gain

Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.

Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug

Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.

LabCorp (LH) Partners HealthVerity to Grow in Drug Development

According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $290.90, marking a +0.98% move from the previous day.

LabCorp (LH) Gets FDA Nod for VirSeq SARS-CoV-2 NGS Test

LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.

The Zacks Analyst Blog Highlights Lilly, Merck, Roche, Pfizer and Moderna

Lilly, Merck, Roche, Pfizer and Moderna have been included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel Nod for PFE, MRNA Young Kids' COVID Jabs & More

FDA panel recommends the use of PFE, MRNA COVID vaccine in kids under five. LLY's Alzheimer's candidate fails to show clinical benefit in study. FDA approves expanded use of LLY's Olumiant.

Kinjel Shah headshot

Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen

Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.

Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata

Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.